Hao Wang

Research output

Research output per year 2001 2003 2004 2015 2016 2019 2020 2021 2022 2023 2024

• 156 Article
• 5 Letter
• 4 Review article
• 2 Comment/debate
• 2 More
  • 1 Editorial
  • 1 Short survey

Research output per year

Research output per year

Search results

• 2024

  Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

  Markowski, M. C., Taplin, M. E., Aggarwal, R., Sena, L. A., Wang, H., Qi, H., Lalji, A., Sinibaldi, V., Carducci, M. A., Paller, C. J., Marshall, C. H., Eisenberger, M., Sanin, D. E., Yegnasubramanian, S., Gomes-Alexandre, C., Ozbek, B., Jones, T., De Marzo, A. M., Denmeade, S. R. & Antonarakis, E., Dec 2024, In: Nature communications. 15, 1, 14.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Nivolumab 100%
  • Androgen 92%
  • Castration 81%
  • therapy 69%
  • cancer 68%
• 2023

  An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 2: Overall Variabilities in Absorbed Dose

  Brosch-Lenz, J., Ke, S., Wang, H., Frey, E., Dewaraja, Y. K., Sunderland, J. & Uribe, C., 2023, In: Journal of Nuclear Medicine. 64, 7, p. 1109-1116 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Single Photon Emission Computed Tomography Computed Tomography 100%
  • Workflow 33%
  • (177lutetium-DOTA(O)Tyr3)octreotate 27%
  • Radiopharmaceuticals 18%
  • Molecular Imaging 18%

• A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma

  Heumann, T., Judkins, C., Li, K., Lim, S. J., Hoare, J., Parkinson, R., Cao, H., Zhang, T., Gai, J., Celiker, B., Zhu, Q., McPhaul, T., Durham, J., Purtell, K., Klein, R., Laheru, D., De Jesus-Acosta, A., Le, D. T., Narang, A., Anders, R., & 9 othersBurkhart, R., Burns, W., Soares, K., Wolfgang, C., Thompson, E., Jaffee, E., Wang, H., He, J. & Zheng, L., Dec 2023, In: Nature communications. 14, 1, 3650.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adjuvant 100%
  • antibodies 95%
  • Nivolumab 94%
  • urelumab 77%
  • Agonist 77%

• Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer

  Denmeade, S. R., Sena, L. A., Wang, H., Antonarakis, E. S. & Markowski, M. C., Jun 2023, In: Oncologist. 28, 6, p. 465-473 9 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Androgen Receptors 100%
  • Androgens 84%
  • Prostatic Neoplasms 73%
  • Castration 63%
  • Therapeutics 15%

• Bone Marrow Relative Biological Effectiveness for a ²¹²Pb-labeled Anti-HER2/neu Antibody

  Liatsou, I., Josefsson, A., Yu, J., Cortez, A., Bastiaannet, R., Velarde, E., Davis, K., Brayton, C., Wang, H., Torgue, J., Hobbs, R. F. & Sgouros, G., Feb 1 2023, In: International Journal of Radiation Oncology Biology Physics. 115, 2, p. 518-528 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Relative Biological Effectiveness 100%
  • bone marrow 90%
  • antibodies 76%
  • Bone Marrow 47%
  • dosage 42%

• Early Normal Tissue Effects and Bone Marrow Relative Biological Effectiveness for an Actinium 225-Labeled HER2/neu-Targeting Antibody

  Liatsou, I., Josefsson, A., Yu, J., Li, Z., Davis, K., Brayton, C., Wang, H., Hobbs, R. F. & Sgouros, G., Nov 15 2023, In: International Journal of Radiation Oncology Biology Physics. 117, 4, p. 1028-1037 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Actinium-225 100%
  • actinium 85%
  • Relative Biological Effectiveness 76%
  • bone marrow 69%
  • antibodies 59%

• First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer

  Sena, L. A., Wang, H. & Denmeade, S. R., Sep 2023, In: Prostate. 83, 12, p. 1127-1132 6 p.

  Research output: Contribution to journal › Editorial › peer-review

• Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector

  Peng, S., Tu, H. F., Cheng, M., Hu, M. H., Tsai, H. L., Tsai, Y. C., Koenig, C., Brayton, C., Wang, H., Chang, Y. N., Arend, R. C., Levinson, K., Roden, R. B. S., Wu, T. C. & Hung, C. F., Oct 2023, In: mBio. 14, 5

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Needles 100%
  • Vaccination 89%
  • CD8 Antigens 88%
  • DNA 62%
  • DNA Vaccines 58%

• Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

  Shenderov, E., De Marzo, A. M., Lotan, T. L., Wang, H., Chan, S., Lim, S. J., Ji, H., Allaf, M. E., Chapman, C., Moore, P. A., Chen, F., Sorg, K., White, A. M., Church, S. E., Hudson, B., Fields, P. A., Hu, S., Denmeade, S. R., Pienta, K. J., Pavlovich, C. P., & 4 othersRoss, A. E., Drake, C. G., Pardoll, D. M. & Antonarakis, E. S., Apr 2023, In: Nature medicine. 29, 4, p. 888-897 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Safety 100%
  • Prostatic Neoplasms 92%
  • Antigen 32%
  • Antibodies 32%
  • Preliminary Data 31%

• Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer after Radical Prostatectomy: The SALV-ENZA Trial

  Tran, P. T., Lowe, K., Tsai, H. L., Song, D. Y., Hung, A. Y., Hearn, J. W. D., Miller, S., Proudfoot, J. A., Deek, M. P., Phillips, R., Lotan, T., Paller, C. J., Marshall, C. H., Markowski, M., Dipasquale, S., Denmeade, S., Carducci, M., Eisenberger, M., Deweese, T. L., Orton, M., & 11 othersDeville, C., Davicioni, E., Liauw, S. L., Heath, E. I., Greco, S., Desai, N. B., Spratt, D. E., Feng, F., Wang, H., Beer, T. M. & Antonarakis, E. S., Feb 20 2023, In: Journal of Clinical Oncology. 41, 6, p. 1307-1317 11 p.

  Research output: Contribution to journal › Article › peer-review

  • MDV 3100 100%
  • Salvage Therapy 80%
  • Prostatectomy 69%
  • Prostate-Specific Antigen 69%
  • Prostatic Neoplasms 53%

• Predictive ability of pancreatic cyst fluid biomarkers: A systematic review and meta-analysis

  Pflüger, M. J., Jamouss, K. T., Afghani, E., Lim, S. J., Rodriguez Franco, S., Mayo, H., Spann, M., Wang, H., Singhi, A., Lennon, A. M. & Wood, L. D., Nov 2023, In: Pancreatology. 23, 7, p. 868-877 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Pancreatic Cyst 100%
  • Cyst Fluid 94%
  • Meta-Analysis 51%
  • Systematic Reviews 50%
  • Cysts 49%

• Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer

  Christenson, E. S., Lee, V., Wang, H., Yarchoan, M., De Jesus-Acosta, A., Azad, N., Gurakar, A., Lin, M. T., Le, D. T., Brennan, D. C., Jaffee, E. M. & Bever, K., Jan 2023, In: Current Oncology. 30, 1, p. 75-84 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Turcot syndrome 100%
  • Organ Transplantation 72%
  • Colorectal Neoplasms 53%
  • Transplants 42%
  • Mutation 37%

• The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation

  Wang, H., Berger, K. N., Miller, E. L., Fu, W., Broglie, L., Goldman, F. D., Konig, H., Lim, S. J., Berg, A. S., Talano, J. A., Comito, M. A., Farag, S. S. & Pu, J. J., Jan 1 2023, In: Therapeutic Advances in Hematology. 14

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cord Blood Stem Cell Transplantation 100%
  • Whole-Body Irradiation 70%
  • Hematopoietic Stem Cell Transplantation 64%
  • Fetal Blood 39%
  • Transplantation 25%

• Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer

  Sena, L. A., Wang, T., Wang, H., Markowski, M. C., Antonarakis, E. S. & Denmeade, S. R., Mar 2023, In: European Journal of Cancer. 181, p. 23-25 3 p.

  Research output: Contribution to journal › Letter › peer-review
• 2022

  A Bayesian Decision-Theoretic Design for Simultaneous Biomarker-Based Subgroup Selection and Efficacy Evaluation

  Wang, Z., Wang, F., Wang, C., Zhang, J., Wang, H., Shi, L., Tang, Z. & Rosner, G. L., 2022, In: Statistics in Biopharmaceutical Research. 14, 4, p. 568-579 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Biomarkers 100%
  • Efficacy 82%
  • Biological Marker 70%
  • Evaluation 56%
  • Subgroup 51%

• Accurate Nonendoscopic Detection of Esophageal Squamous Cell Carcinoma Using Methylated DNA Biomarkers

  Esophageal Squamous Cell Carcinoma Consortium, Aug 2022, In: Gastroenterology. 163, 2, p. 507-509.e2

  Research output: Contribution to journal › Short survey › peer-review

  Open Access

• Association of Tumor Site with the Prognosis and Immunogenomic Landscape of Human Papillomavirus-Related Head and Neck and Cervical Cancers

  Zhu, G., Amin, N., Herberg, M. E., Maroun, C. A., Wang, H., Guller, M., Gourin, C. G., Rooper, L. M., Vosler, P. S., Tan, M., D'Souza, G., Koch, W. M., Eisele, D. W., Seiwert, T. Y., Fakhry, C., Pardoll, D. M. & Mandal, R., Jan 2022, In: JAMA Otolaryngology - Head and Neck Surgery. 148, 1, p. 70-79 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Head and Neck Neoplasms 100%
  • Uterine Cervical Neoplasms 91%
  • Neoplasms 32%
  • Squamous Cell Carcinoma 23%
  • Survival 15%

• Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer

  Baretti, M., Zhu, Q., Fu, W., Meyer, J., Wang, H., Anders, R. A. & Azad, N. S., 2022, In: Oncotarget. 13, 1, p. 907-917 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor-Infiltrating Lymphocytes 100%
  • Mucins 84%
  • Chemoradiotherapy 84%
  • Rectal Neoplasms 80%
  • Ligands 55%

• Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss

  Markowski, M. C., Wang, H., De Marzo, A. M., Schweizer, M. T., Antonarakis, E. S. & Denmeade, S. R., Jul 2022, In: European Urology Open Science. 41, p. 112-115 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

  • Castration 100%
  • Androgens 82%
  • Prostatic Neoplasms 71%
  • Testosterone 47%
  • Tumor Suppressor Genes 35%

• Colon Tumors in Enterotoxigenic Bacteroides fragilis (ETBF)Colonized Mice Do Not Display a Unique Mutational Signature but Instead Possess Host-Dependent Alterations in the APC Gene

  Allen, J., Huber, A. R., Pleguezuelos-Manzano, C., Puschhof, J., Wu, S., Wu, X., Boot, C., Saftien, A., O’Hagan, H. M., Wang, H., van Boxtel, R., Clevers, H. & Sears, C. L., Jun 2022, In: Microbiology Spectrum. 10, 3

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • APC Genes 100%
  • Bacteroides fragilis 95%
  • tumor 75%
  • colon 70%
  • Colon 57%

• Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics

  Sutera, P., Van Der Eecken, K., Kishan, A. U., Hamid, A., Grist, E., Attard, G., Lotan, T., Mendes, A. A., Paller, C. J., Carducci, M. A., Ross, A., Wang, H., Pienta, K., Feng, F. Y., Antonarakis, E. S., Ost, P., Song, D. Y., Greco, S., Deville, C., DeWeese, T., & 2 othersTran, P. T. & Deek, M. P., Apr 2022, In: Prostate Cancer and Prostatic Diseases. 25, 4, p. 713-719 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Castration 100%
  • Genomics 91%
  • Prostatic Neoplasms 71%
  • Survival 33%
  • Progression-Free Survival 27%

• Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials

  Sidiropoulos, D. N., Stein-O'Brien, G. L., Danilova, L., Gross, N. E., Charmsaz, S., Xavier, S., Leatherman, J., Wang, H., Yarchoan, M., Jaffee, E. M., Fertig, E. J. & Ho, W. J., Oct 10 2022, In: JCI Insight. 7, 19, e160398.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Immunologic Monitoring 100%
  • Immunotherapy 68%
  • Clinical Trials 50%
  • T-Lymphocytes 47%
  • Machine Learning 17%

• Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial

  Hill, C. S., Rosati, L., Wang, H., Tsai, H. L., He, J., Hacker-Prietz, A., Laheru, D. A., Zheng, L., Sehgal, S., Bernard, V., Le, D. T., Pawlik, T. M., Weiss, M. J., Narang, A. K. & Herman, J. M., Nov 1 2022, In: Practical Radiation Oncology. 12, 6, p. 511-523 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Non-Randomized Controlled Trials 100%
  • Radiosurgery 94%
  • Adenocarcinoma 67%
  • Drug Therapy 50%
  • Pancreatic Neoplasms 37%

• Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy

  Li, K., Tandurella, J. A., Gai, J., Zhu, Q., Lim, S. J., Thomas, D. L., Xia, T., Mo, G., Mitchell, J. T., Montagne, J., Lyman, M., Danilova, L. V., Zimmerman, J. W., Kinny-Köster, B., Zhang, T., Chen, L., Blair, A. B., Heumann, T., Parkinson, R., Durham, J. N., & 11 othersNarang, A. K., Anders, R. A., Wolfgang, C. L., Laheru, D. A., He, J., Osipov, A., Thompson, E. D., Wang, H., Fertig, E. J., Jaffee, E. M. & Zheng, L., Nov 14 2022, In: Cancer cell. 40, 11, p. 1374-1391.e7

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Neoadjuvant Therapy 100%
  • Tumor Microenvironment 90%
  • Nivolumab 78%
  • Adenocarcinoma 67%
  • T-Lymphocytes 53%

• PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study

  Denmeade, S., Lim, S. J., Isaaccson Velho, P. & Wang, H., Dec 1 2022, In: Prostate. 82, 16, p. 1529-1536 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Prostate-Specific Antigen 100%
  • Androgens 89%
  • Survival 19%
  • Therapeutics 16%
  • abiraterone 15%

• The application of salvage surgery improves the quality of life and overall survival of extensively recurrent head and neck cancer after multiple operation plus radiotherapy

  Zhang, L., Xu, Q., Liu, H., Li, B., Wang, H., Liu, C., Li, J., Yang, B., Qin, L., Han, Z. & Feng, Z., Nov 1 2022, In: Frontiers in Oncology. 12, 1017630.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Head and Neck Neoplasms 100%
  • Radiotherapy 68%
  • Quality of Life 64%
  • Survival 55%
  • Superficial Back Muscles 29%

• The Impact of Clinical and Pathological Features on Intraductal Papillary Mucinous Neoplasm Recurrence after Surgical Resection: Long-Term Follow-Up Analysis

  Pflüger, M. J., Griffin, J. F., Hackeng, W. M., Kawamoto, S., Yu, J., Chianchiano, P., Shin, E., Lionheart, G., Tsai, H. L., Wang, H., Rezaee, N., Burkhart, R. A., Cameron, J. L., Thompson, E. D., Wolfgang, C. L., He, J., Brosens, L. A. A. & Wood, L. D., Jun 1 2022, In: Annals of surgery. 275, 6, p. 1165-1174 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Recurrence 100%
  • Neoplasms 56%
  • Pancreatic Intraductal Neoplasms 33%
  • High-Throughput Nucleotide Sequencing 20%
  • Pancreatic Neoplasms 20%

• Vaccination with human alphapapillomavirus-derived L2 multimer protects against human betapapillomavirus challenge, including in epidermodysplasia verruciformis model mice

  Olczak, P., Wong, M., Tsai, H. L., Wang, H., Kirnbauer, R., Griffith, A. J., Lambert, P. F. & Roden, R., Oct 2022, In: Virology. 575, p. 63-73 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Alphapapillomavirus 100%
  • Betapapillomavirus 94%
  • Epidermodysplasia Verruciformis 78%
  • Vaccination 38%
  • Uterine Cervical Neoplasms 29%
• 2021

  A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts

  Markowski, M. C., Wang, H., Sullivan, R., Rifkind, I., Sinibaldi, V., Schweizer, M. T., Teply, B. A., Ngomba, N., Fu, W., Carducci, M. A., Paller, C. J., Marshall, C. H., Eisenberger, M. A., Luo, J., Antonarakis, E. S. & Denmeade, S. R., May 2021, In: European Urology. 79, 5, p. 692-699 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • abiraterone 100%
  • MDV 3100 96%
  • Castration 72%
  • Androgens 60%
  • Prostatic Neoplasms 52%
  3 Scopus citations

• Bacterial-driven inflammation and mutant braf expression combine to promote murine colon tumorigenesis that is sensitive to immune checkpoint therapy

  Destefano Shields, C. E., White, J. R., Chung, L., Wenzel, A., Hicks, J. L., Tam, A. J., Chan, J. L., Dejea, C. M., Fan, H., Michel, J., Maiuri, A. R., Sriramkumar, S., Podicheti, R., Rusch, D. B., Wang, H., De Marzo, A. M., Besharati, S., Anders, R. A., Baylin, S. B., O’hagan, H. M., & 2 othersHousseau, F. & Sears, C. L., Jul 2021, In: Cancer discovery. 11, 7, p. 1792-1807 16 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Colon 100%
  • Carcinogenesis 95%
  • Bacteroides fragilis 82%
  • Inflammation 73%
  • Colorectal Neoplasms 61%

• Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy

  Sena, L. A., Wang, H., Lim ScM, S. J., Rifkind, I., Ngomba, N., Isaacs, J. T., Luo, J., Pratz, C., Sinibaldi, V., Carducci, M. A., Paller, C. J., Eisenberger, M. A., Markowski, M. C., Antonarakis, E. S. & Denmeade, S. R., Feb 2021, In: European Journal of Cancer. 144, p. 302-309 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Castration 100%
  • Androgen Receptors 97%
  • Androgens 82%
  • Prostatic Neoplasms 71%
  • abiraterone 19%

• Differential activity of PARP inhibitors in BRCA1- Versus BRCA2-altered metastatic castration-resistant prostate cancer

  Taza, F., Holler, A. E., Fu, W., Wang, H., Adra, N., Albany, C., Ashkar, R., Cheng, H. H., Sokolova, A. O., Agarwal, N., Kessel, A., Bryce, A., Nafissi, N., Barata, P., Oliver Sartor, A., Bastos, D., Smaletz, O., Berchuck, J. E., Taplin, M. E., Aggarwal, R., & 6 othersSternberg, C. N., Vlachostergios, P. J., Alva, A. S., Su, C., Marshall, C. H. & Antonarakis, E. S., 2021, In: JCO Precision Oncology. 5, p. 1200-1220 21 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Poly(ADP-ribose) Polymerase Inhibitors 100%
  • Castration 83%
  • Prostatic Neoplasms 59%
  • Prostate-Specific Antigen 48%
  • rucaparib 33%

• Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer

  Nizialek, E., Lim, S. J., Wang, H., Isaacsson Velho, P., Yegnasubramanian, S. & Antonarakis, E. S., Jun 15 2021, In: Prostate. 81, 9, p. 572-579 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Prostatic Neoplasms 100%
  • Hormones 88%
  • Mutation 43%
  • Survival 32%
  • Progression-Free Survival 26%

• Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial

  Shenderov, E., Boudadi, K., Fu, W., Wang, H., Sullivan, R., Jordan, A., Dowling, D., Harb, R., Schonhoft, J., Jendrisak, A., Carducci, M. A., Eisenberger, M. A., Eshleman, J. R., Luo, J., Drake, C. G., Pardoll, D. M. & Antonarakis, E. S., May 1 2021, In: Prostate. 81, 6, p. 326-338 13 p.

  Research output: Contribution to journal › Article › peer-review

  • MDV 3100 100%
  • Ipilimumab 95%
  • Nivolumab 92%
  • Non-Randomized Controlled Trials 79%
  • Castration 75%
  1 Scopus citations

• Quantitation of cancer treatment response by 2-[¹⁸F]FDG PET/CT: multi-center assessment of measurement variability using AUTO-PERCIST™

  QIN PET Readers, 2021, In: EJNMMI Research. 11, 1, 15.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Fluorodeoxyglucose F18 100%
  • Neoplasms 30%
  • Software 17%
  • Positron Emission Tomography Computed Tomography 17%
  • Therapeutics 15%

• Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer

  Marshall, C. H., Fu, W., Wang, H., Park, J. C., DeWeese, T. L., Tran, P. T., Song, D. Y., King, S., Afful, M., Hurrelbrink, J., Manogue, C., Cotogno, P., Moldawer, N. P., Barata, P. C., Drake, C. G., Posadas, E. M., Armstrong, A. J., Sartor, O. & Antonarakis, E. S., Mar 2021, In: Clinical Cancer Research. 27, 6, p. 1623-1630 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radium-223 100%
  • Castration 66%
  • Prostatic Neoplasms 47%
  • Bone and Bones 36%
  • Progression-Free Survival 18%
  3 Scopus citations

• TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer

  Denmeade, S. R., Wang, H., Agarwal, N., Smith, D. C., Schweizer, M. T., Stein, M. N., Assikis, V., Twardowski, P. W., Flaig, T. W., Szmulewitz, R. Z., Holzbeierlein, J. M., Hauke, R. J., Sonpavde, G., Garcia, J. A., Hussain, A., Sartor, O., Mao, S., Cao, H., Fu, W., Wang, T., & 8 othersAbdallah, R., Lim, S. J., Bolejack, V., Paller, C. J., Carducci, M. A., Markowski, M. C., Eisenberger, M. A. & Antonarakis, E. S., Apr 20 2021, In: Journal of Clinical Oncology. 39, 12, p. 1371-1382 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • MDV 3100 100%
  • Castration 75%
  • Androgens 62%
  • Testosterone 59%
  • Prostatic Neoplasms 53%

• Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer

  Sena, L. A., Fountain, J., Isaacsson Velho, P., Lim, S. J., Wang, H., Nizialek, E., Rathi, N., Nussenzveig, R., Maughan, B. L., Velez, M. G., Ashkar, R., Larson, A. C., Pritchard, C. C., Adra, N., Bryce, A. H., Agarwal, N., Pardoll, D. M., Eshleman, J. R., Lotan, T. L. & Antonarakis, E. S., Feb 2021, In: Oncologist. 26, 2, p. e270-e278

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Frameshift Mutation 100%
  • DNA Mismatch Repair 97%
  • Immunotherapy 71%
  • Prostatic Neoplasms 64%
  • Neoplasms 26%
  4 Scopus citations
• 2020

  An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma

  Bever, K. M., Borazanci, E. H., Thompson, E. A., Durham, J. N., Pinero, K., Jameson, G. S., Vrana, A., Liu, M., Wilt, C., Wu, A. A., Fu, W., Wang, H., Yin, Y., Leal, J. P., de Jesus-Acosta, A., Zheng, L., Laheru, D. A., von Hoff, D. D., Jaffee, E. M., Powell, J. D., & 1 othersLe, D. T., May 26 2020, In: Oncotarget. 11, 21, p. 1929-1941 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Induction Chemotherapy 100%
  • Metformin 89%
  • Sirolimus 88%
  • Adenocarcinoma 65%
  • Maintenance 44%
  1 Scopus citations

• A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

  Hasan, H., Deek, M. P., Phillips, R., Hobbs, R. F., Malek, R., Radwan, N., Kiess, A. P., Dipasquale, S., Huang, J., Caldwell, T., Leitzel, J., Wendler, D., Wang, H., Thompson, E., Powell, J., Dudley, S., Deville, C., Greco, S. C., Song, D. Y., Deweese, T. L., & 11 othersGorin, M. A., Rowe, S. P., Denmeade, S., Markowski, M., Antonarakis, E. S., Carducci, M. A., Eisenberger, M. A., Pomper, M. G., Pienta, K. J., Paller, C. J. & Tran, P. T., Jun 1 2020, In: BMC cancer. 20, 1, 492.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radium-223 100%
  • Prostatic Neoplasms 47%
  • Neoplasm Metastasis 37%
  • Hormones 25%
  • Progression-Free Survival 21%
  3 Scopus citations

• Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-Reply

  Lu, S., Wang, H. & Taube, J. M., Feb 2020, In: JAMA Oncology. 6, 2, p. 299 1 p.

  Research output: Contribution to journal › Letter › peer-review
  1 Scopus citations

• Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma

  Anagnostou, V., Bruhm, D. C., Niknafs, N., White, J. R., Shao, X. M., Sidhom, J. W., Stein, J., Tsai, H. L., Wang, H., Belcaid, Z., Murray, J., Balan, A., Ferreira, L., Ross-Macdonald, P., Wind-Rotolo, M., Baras, A. S., Taube, J., Karchin, R., Scharpf, R. B., Grasso, C., & 4 othersRibas, A., Pardoll, D. M., Topalian, S. L. & Velculescu, V. E., Nov 17 2020, In: Cell Reports Medicine. 1, 8, 100139.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mutation 100%
  • Melanoma 98%
  • T-Lymphocytes 73%
  • Neoplasms 38%
  • B-Lymphocyte Subsets 37%
  4 Scopus citations

• Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial

  Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A. E., Gorin, M. A., Deville, C., Greco, S. C., Wang, H., Denmeade, S. R., Paller, C. J., Dipasquale, S., Deweese, T. L., Song, D. Y., Wang, H., Carducci, M. A., Pienta, K. J., & 6 othersPomper, M. G., Dicker, A. P., Eisenberger, M. A., Alizadeh, A. A., Diehn, M. & Tran, P. T., May 2020, In: JAMA Oncology. 6, 5, p. 650-659 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radiosurgery 100%
  • Prostatic Neoplasms 71%
  • Observation 64%
  • Radiotherapy 62%
  • Randomized Controlled Trials 61%
  135 Scopus citations

• Pan-tumor pathologic scoring of response to PD-(L)1 blockade

  Stein, J. E., Lipson, E. J., Cottrell, T. R., Forde, P. M., Anders, R. A., Cimino-Mathews, A., Thompson, E. D., Allaf, M. E., Yarchoan, M., Feliciano, J., Wang, H., Jaffee, E. M., Pardoll, D. M., Topalian, S. L. & Taube, J. M., Feb 1 2020, In: Clinical Cancer Research. 26, 3, p. 545-551 7 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Neoplasms 100%
  • Merkel Cells 47%
  • Specimen Handling 42%
  • Drug Therapy 36%
  • Hematoxylin 30%
  22 Scopus citations

• Risk Factors for Progression of Barrett’s Esophagus to High Grade Dysplasia and Esophageal Adenocarcinoma

  Kambhampati, S., Tieu, A. H., Luber, B., Wang, H. & Meltzer, S. J., Dec 1 2020, In: Scientific reports. 10, 1, 4899.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Barrett Esophagus 100%
  • Adenocarcinoma 64%
  • Caffeine 28%
  • Adenoma 17%
  • Endoscopy 16%
  5 Scopus citations

• Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate

  Heaphy, C. M., Haffner, M. C., Graham, M. K., Lim, D., Davis, C., Corey, E., Epstein, J. I., Eisenberger, M. A., Wang, H., De Marzo, A. M., Meeker, A. K. & Lotan, T. L., Jul 2020, In: Human pathology. 101, p. 70-79 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Neuroendocrine Carcinoma 100%
  • Telomere 85%
  • Prostate 64%
  • Adenocarcinoma 60%
  • Missense Mutation 7%
  1 Scopus citations

• Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype

  Lu, C., Terbuch, A., Dolling, D., Yu, J., Wang, H., Chen, Y., Fountain, J., Bertan, C., Sharp, A., Carreira, S., Isaacs, W. B., Antonarakis, E. S., De Bono, J. S. & Luo, J., Sep 2020, In: Annals of Oncology. 31, 9, p. 1178-1185 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • abiraterone 100%
  • MDV 3100 96%
  • Castration 72%
  • Prostatic Neoplasms 52%
  • Genotype 47%
  6 Scopus citations

• Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis

  Osipov, A., Lim, S. J., Popovic, A., Azad, N. S., Laheru, D. A., Zheng, L., Jaffee, E. M., Wang, H. & Yarchoan, M., Sep 15 2020, In: Clinical Cancer Research. 26, 18, p. 4842-4851 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor Burden 100%
  • Meta-Analysis 78%
  • Regression Analysis 69%
  • Survival 21%
  • Neoplasms 18%
  8 Scopus citations

• Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma

  Ho, W. J., Danilova, L., Lim, S. J., Verma, R., Xavier, S., Leatherman, J. M., Sztein, M. B., Fertig, E. J., Wang, H., Jaffee, E. & Yarchoan, M., Apr 16 2020, In: Journal for immunotherapy of cancer. 8, 1, e000394.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hepatocellular Carcinoma 100%
  • Tumor Microenvironment 86%
  • Ligands 58%
  • Meta-Analysis 30%
  • Programmed Cell Death 1 Receptor 29%
  4 Scopus citations

• Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer

  Isaacsson Velho, P., Fu, W., Wang, H., Mirkheshti, N., Qazi, F., Lima, F. A. S., Shaukat, F., Carducci, M. A., Denmeade, S. R., Paller, C. J., Markowski, M. C., Marshall, C. H., Eisenberger, M. A. & Antonarakis, E. S., Jan 2020, In: European Urology. 77, 1, p. 14-21 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • abiraterone 100%
  • MDV 3100 96%
  • Castration 72%
  • Prostatic Neoplasms 52%
  • Mutation 36%
  20 Scopus citations